

## Curriculum Vitae Prof. Dr. Jürgen Behr

**Name:** Jürgen Behr;

**Dob** September 6<sup>th</sup> 1960, Bamberg, Germany

**Position:** Professor and Chair Pneumology LMU, Head of Department of Medicine V (Pneumology), Ludwig Maximilian University of Munich (LMU)

### Academic and professional career

Since 2013 Chair Pneumology at the Ludwig-Maximilians University Munich (LMU)

since 2013 Director, Department of Medicine V - Pneumology, University Hospital LMU Munich

since 2013 Co-Chair, Comprehensive Pneumology Center, Ludwig Maximilian University of Munich, University Hospital Munich, Helmholtz Zentrum Munich, and Asklepios

since 2013 P.I., German Center for Lung Research (DZL)

since 2020 Consultant Professor, Asklepios Lung Hospital Munich-Gauting

2013-2020 Hospital President, Asklepios Lung Hospital Munich-Gauting

2010-2012 Director and Full Professor, Department of Internal Medicine III-Pneumology, Ruhr-University-Bochum

2002-2010 Associate Professor of Internal Medicine, Respiratory Diseases, Ludwig Maximilian University of Munich (LMU)

2001-2010 Head of Div. of Respiratory Diseases, Department of Internal Med. I, Ludwig Maximilian University of Munich (LMU)

1997-2001 Attending Physician of the Intensive Care Unit (1997-98) and of the Div. of Pulmonary Diseases (1998-) at the Department of Internal Medicine I, Ludwig Maximilian University of Munich (LMU)

1996 Habilitation, Internal Medicine, Ludwig Maximilian University of Munich (LMU)

1987 Doctorate in Medicine, Ludwig Maximilian University of Munich (LMU)

1986-1996 Internship and Residency, Department of Internal Medicine I, Ludwig Maximilian University of Munich (LMU)

1979 - 1985 Studies of Human Medicine, Ludwig Maximilian University of Munich (LMU) (Scholarship from Bavarian State Ministry of Science and the Arts)

### Functions in scientific societies and committees

Since 2023 Editorial board of the American Journal of Respiratory and Critical Care Medicine

2019 President, Annual Congress of German Respiratory Society (DGP)

2002-2025 Chair, Guideline Committee, German Respiratory Society (DGP)

2016-2018 Chairman, Scientific Association for the Treatment of Lung Diseases (WATL)

- 2016 Congress President, “Rare Lung Diseases” (WATL), Berlin, Germany
- 2014 Co-Chair, Annual Congress of the European Respiratory Society
- Since 2013 Chair Stiftung Atemweg
- 2009-2012 ERS Delegate of the ATS/ERS Interstitial Lung Disease Classification Committee
- 2008-2012 ERS Delegate of the ATS/ERS Lung Transplantation Guideline Committee
- 2006-2018 ERS Delegate of the ATS/ERS/JRS/ALAT IPF-Guideline Committee

### Scientific focus

My main scientific focus is the pathogenesis, diagnosis and treatment of acute and chronic lung diseases with a special focus on interstitial lung disease, pulmonary hypertension, and lung transplantation. I am also engaged in clinical research in the area of lung cancer, where we are one of the leading centers in Germany, as well as Asthma, COPD, Cystic Fibrosis and non-CF bronchiectasis. My research work includes clinical trials with novel therapeutics as well as basic research in the context of the cooperative work with the institute of Lung Health and Immunity which is part of the Comprehensive Pneumology Centre Munich, hosted at the Helmholtz Centre Munich.

### Citation record

546 publications listed in PubMed. Total citations: 63.165; h-index: 101; h-index since 2021: 66 (Google Scholar, March 2026).

### Top ten publications

1: Nathan SD, Smith P, Deng C, De Salvo M, Wuyts W, Pavie-Gallegos J, Song JW, Kramer MR, King CS, Mackintosh JA, Chambers D, Miranda GV, Breytenbach N, Peterson L, Bell H, Flaherty KR, **Behr J\***, Cottin V\*, **\*Co-Senior authors**, for the TETON-2 Trial Investigators. Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis: The TETON-2 Trial. **New Engl J Med**, accepted, expected online first in March 2026

2: **Behr J**, Salisbury ML, Walsh SLF, Podolanczuk AJ, Hariri LP, Hunninghake GM, Kolb M, Ryerson CJ, Cottin V, Beasley MB, Corte T, Glanville AR, Adegunsoye A, Hogaboam C, Wuyts WA, Noth I, Oldham JM, Richeldi L, Raghu G, Wells AU. The Role of Inflammation and Fibrosis in Interstitial Lung Disease Treatment Decisions. **Am J Respir Crit Care Med**. 2024 Aug 15;210(4):392-400. doi: 10.1164/rccm.202401-0048PP. PMID: 38484133; PMCID: PMC12039538.

3: Raghu G, Mouded M, Chambers DC, Martinez FJ, Richeldi L, Lancaster LH, Hamblin MJ, Gibson KF, Rosas IO, Prasse A, Zhao G, Serenko M, Novikov N, McCurley A, Bansal P, Stebbins C, Arefayene M, Ibejunjo S, Violette SM, Gallagher D, **Behr J**. A Phase IIb Randomized Clinical Study of an Anti- $\alpha\beta 6$  Monoclonal Antibody in Idiopathic Pulmonary Fibrosis. **Am J Respir Crit Care Med**. 2022 Nov 1;206(9):1128-1139. doi: 10.1164/rccm.202112-2824OC. PMID: 35771569.

4: Neurohr C, Kneidinger N, Ghiani A, Monforte V, Knoop C, Jaksch P, Parmar J, Ussetti P, Sole A, Müller Quernheim J, Kessler R, Wirtz H, Boerner G, Denk O, Prante Fernandes S, **Behr J**. A randomized controlled trial of liposomal cyclosporine A for inhalation in the prevention of bronchiolitis obliterans syndrome following lung transplantation. **Am J Transplant**. 2022 Jan;22(1):222-229. doi: 10.1111/ajt.16858. Epub 2021 Oct 18. PMID: 34587371.

5: **Behr J**, Prasse A, Kreuter M, Johow J, Rabe KF, Bonella F, Bonnet R, Grohe C, Held M, Wilkens H, Hammerl P, Koschel D, Blaas S, Wirtz H, Ficker JH, Neumeister W, Schönfeld N, Claussen M, Kneidinger N, Frankenberger M, Hummler S, Kahn N, Tello S, Freise J, Welte T, Neuser P, Günther A; RELIEF investigators. Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial. **Lancet Respir Med**. 2021 May;9(5):476-486. doi: 10.1016/S2213-2600(20)30554-3. Epub 2021 Mar 30. PMID: 33798455.

6: **Behr J**, Nathan SD, Wuyts WA, Mogulkoc Bishop N, Bouros DE, Antoniou K, Guiot J, Kramer MR, Kirchgaessler KU, Bengus M, Gilberg F, Perjesi A, Harari S, Wells AU. Efficacy and safety of sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: a double-blind, randomised, placebo-controlled, phase 2b trial. **Lancet Respir Med**. 2021 Jan;9(1):85-95. doi: 10.1016/S2213-2600(20)30356-8. Epub 2020 Aug 18.

7: **Behr J**, Prasse A, Wirtz H, Koschel D, Pittrow D, Held M, Klotsche J, Andreas S, Claussen M, Grohé C, Wilkens H, Hagemeyer L, Skowasch D, Meyer JF, Kirschner J, Gläser S, Kahn N, Welte T, Neurohr C, Schwaiblmair M, Bahmer T, Oqueka T, Frankenberger M, Kreuter M. Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis: long-term results of the INSIGHTS-IPF registry. **Eur Respir J**. 2020 Aug 13;56(2):1902279. doi: 10.1183/13993003.02279-2019. PMID: 32381492.

8: Kolb M, Raghu G, Wells AU, **Behr J**, Richeldi L, Schinzel B, Quaresma M, Stowasser S, Martinez FJ; INSTAGE Investigators. Nintedanib plus Sildenafil in Patients with Idiopathic Pulmonary Fibrosis. **N Engl J Med**. 2018 Nov 1;379(18):1722-1731. doi: 10.1056/NEJMoa1811737. Epub 2018 Sep 15. PMID: 30220235.

9: **Behr J**, Bendstrup E, Crestani B, Günther A, Olschewski H, Sköld CM, Wells A, Wuyts W, Koschel D, Kreuter M, Wallaert B, Lin CY, Beck J, Albera C. Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial. **Lancet Respir Med**. 2016 Jun;4(6):445-53. doi: 10.1016/S2213-2600(16)30044-3. Epub 2016 May 5. PMID: 27161257.

10: Demedts M, **Behr J**, Buhl R, Costabel U, Dekhuijzen R, Jansen HM, MacNee W, Thomeer M, Wallaert B, Laurent F, Nicholson AG, Verbeken EK, Verschakelen J,

Flower CD, Capron F, Petruzzelli S, De Vuyst P, van den Bosch JM, Rodriguez-Becerra E, Corvasce G, Lankhorst I, Sardina M, Montanari M; IFIGENIA Study Group. High-dose acetylcysteine in idiopathic pulmonary fibrosis. **N Engl J Med.** 2005 Nov 24;353(21):2229-42. doi: 10.1056/NEJMoa042976. PMID: 16306520.

**List of relevant third-party funding (2020 to 2025)**

2020-2025	BMBF – DZL	7.000.000,00 €
2020-2025	Industry Funding	1.500.000,00 €
2020-2025	Foundations	450.000,00 €
2020	DFG AOBJ: 671380	200.000,00 €
2020	BMBF Clinical Trials	600.000,00 €
2023	DFG AOBJ: 698845	320.000,00 €
2024	BMBF „Precious PCLS“	175.000,00 €
2026	Munch One (M1)	1.500.000,00 €

Munich, 10.03.2026



Prof. Dr. Jürgen Behr